Posts

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

/by

Authors: Dominique Melck, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, et al
Endocrinology, January 2000
—
Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we rep…

Read more

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

/by

Authors: Luciano De Petrocellis, Dominique Melck, Antonella Palmisano, Tiziana Bisogno, et al
PNAS, 7 July 1998
—
Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. Anandamide dose-dependently inhi…

Read more